Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia
In children with HeFH, evolocumab plus statin treatment up to 104 weeks led to regression in carotid arterial wall thickening.
Authors
- Andrea Ruzza (ORCID: https://orcid.org/0000-0001-6827-0718)
- Claudia Stefanutti (ORCID: https://orcid.org/0000-0003-3448-2426)
- Albert Wiegman (ORCID: https://orcid.org/0000-0001-6223-5671)
- Raul D. Santos (ORCID: https://orcid.org/0000-0002-9764-6320)
- Frederick Johan Raal (ORCID: https://orcid.org/0000-0002-9170-7938)
- Ian Bridges (ORCID: https://orcid.org/0000-0002-3317-3528)
- John J.P. Kastelein (ORCID: https://orcid.org/0000-0003-2018-4532)
- François Mach (ORCID: https://orcid.org/0000-0003-3178-9131)
- Daniel Gaudet (ORCID: https://orcid.org/0000-0002-5185-3666)
- Bei Wang (ORCID: https://orcid.org/0000-0001-9336-4505)
- Ajay Bhatia
- Ilse K. Luirink
- G. Kees Hovingh
Institutions
- Université du Québec à Chicoutimi (CA)
- Amgen (United States) (US)
- Universidade de São Paulo (BR)
- University of the Witwatersrand (ZA)
- Hospital Israelita Albert Einstein (BR)
- Policlinico Umberto I (IT)
- University Hospital of Geneva (CH)
- Amgen (United Kingdom) (GB)
- Amsterdam University Medical Centers (NL)
- Geneva College (US)
- Université de Montréal (CA)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2024-11-12
- DOI
- https://doi.org/10.1093/eurjpc/zwae369
- Citations
- 9
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 5.15